This free guide aims to "help educators and academic leaders introduce didactic psychedelic therapy coursework into their programs. Whether you’re looking for ways to start the conversation with colleagues, seeking resources, or simply looking to build a teaching cohort, this introductory toolkit has everything you need to get started.

Have you ever wondered what you should say to a patient who asks whether they should try a psychedelic? ... If you have, the following case vignette and discussion should prove useful.

This paper focuses on the development of robust infrastructure in Germany, which will support the roll out of PAT, and details ethical considerations, training protocols, and governmental roles in the formulation of treatment frameworks. This approach aims not only to guide Germany in adopting PAT but also to influence broader European policy, ensuring that patients receive ethically sound and proficient care. The findings suggest pathways for Europe to reclaim its historical lead in psychiatric and therapeutic innovation.

These results suggest that the quality and depth of the psychedelic experience, rather than the frequency of use, are primarily linked to psychological flexibility, particularly Acceptance, and overall well-being.

Anatomical and functional brain changes were detected from one-hour to one-month after a single high-dose (25 mg) of psilocybin. Increases in cognitive flexibility, psychological insight, and well-being were seen at one-month.

But is there not something paradoxical or even Quixotic about the idea of making Dionysian experiences ‘safe’. Dionysus is not safe. He is the god of transgression, of ecstasy, of going beyond limits.

While users typically expected alleged MDMA samples to contain only MDMA, more than half of the submitted MDMA samples were misrepresented in some manner. Despite high levels of misrepresentation, MDMA quality has stabilized at relatively high levels in recent years.

Using the conference experience as the glue, we will attempt to mold these articles into an image of the current state of psychedelic research, one of the most interesting and potentially important areas in addiction science.

PAP significantly improved anxiety, depression, interpersonal sensitivity, hostility, obsession–compulsion and somatization without inducing any lasting phobia, paranoia or psychosis. Clinical improvements were consistent between trials. Together, our findings suggest that PAP has the potential to be a comprehensive mental health treatment for patients with cancer.

The antidepressant effects of psychedelics may be overestimated in studies with pre-post single-arm, non-active-drugs-as placebo, and waitlist-control designs. Restricted sample size, difficulty with establishing blinding for participants, and over expectancy limit the estimation of the antidepressant effect of psychedelic-assisted therapy.

We explore psilocybin as a potential treatment option for PTSD by examining the neurobiology of PTSD as well as psilocybin’s mechanism of action. Based on both pharmacodynamic and psychoanalytic principles, psilocybin may be an underexplored treatment option for patients with PTSD, though further research is required.

Results suggest that most meditators found psychedelic use to have a positive influence on their meditation practice, with: 1) regularity of psychedelic use, 2) the setting of intentions for psychedelic use, 3) having an agreeable personality, and 4) reported use of N,N-DMT being the most likely predictors of perceiving psychedelic use as beneficial.

At 1-month follow-up, the meditators who received DMT and harmine rated their experience as significantly more personally meaningful, spiritually significant, and well-being-enhancing than the meditators who received placebo.

The intervention (for PTSD) is composite, and its outcomes assumed to result from MDMA facilitating the effects of psychotherapy. In this Viewpoint, we argue that the psychotherapy component plays a critical role in assessing the validity of the trials.

I believe this will be one of the next conditions, if not the next condition, to be considered for the designation of innovative treatment in future psilocybin regulation in the United States

This group of US pharmacists have started a website where they advertise: "Receive an instant, evidence-based report on psilocybin mushroom interactions with your medications and health conditions."

The results indicate that Idealism specifically, not non-physicalist beliefs generally, mediate a link between the use of psychedelics and wellbeing. Future research is required to establish whether the link is causal, and to understand what the Idealism factor means.

This study indicates the positive effects of microdosing psychedelics on ADHD symptoms and emotion regulation in adults with severe ADHD symptoms while lacking evidence for effects on empathy.

These data suggest that the IPPS is predictive of relevant acute features of the psychedelic experience in a broad range of contexts. We hope that this brief 9-item scale will be widely adopted for improved knowledge of psychedelic preparedness in controlled settings and beyond.

Patients showed a significant decrease in MADRS scores, and the greatest predictor of antidepressant outcome was relaxation during the PAT session.